XML 30 R19.htm IDEA: XBRL DOCUMENT v3.25.1
Note 12 - Subsequent Events
 3 Months Ended
Mar. 31, 2025
Notes to Financial Statements  
Subsequent Events [Text Block]

(12)

Subsequent Events

 

On April 22, 2025, we entered into a Securities Purchase and Registration Rights Agreement relating to a private placement with certain qualified institutional buyers and institutional accredited investors, which closed on April 23, 2025. Pursuant to the agreement, we sold 406,818 shares of our common stock, and warrants to purchase an aggregate of 406,818 shares of our common stock at an exercise price equal to $1.905 per share, which are exercisable at any time before the earlier of April 24, 2030 or the approval by the Japanese Pharmaceuticals and Medical Devices Agency of our application of our CardiAMP Cell Therapy System. The gross proceeds of the Offering were $775,000 before deducting transaction expenses.

 

During the period from April 1, 2025 to May 13, 2025 we sold an aggregate of 88,888 shares of common stock under the ATM Offerings at then-market prices for total gross proceeds of $234,000. On April 4, 2025, we filed a prospectus supplement that updated the maximum aggregate offering amount that may be sold pursuant to the Sales Agreement to approximately $1.8 million.